The lifetime risk of cancer is on the rise owing to increasing life expectancy and the increased incidence associated with advanced age.
In general, when cancer develops or recurs in IBD patients, this may be related to the chronic intestinal inflammation, have no link with IBD or its treatment, and/or may be potentially influenced by the immunosuppressive drugs.
Health-care providers caring for patients with IBD are often faced with the challenges of managing the disease in patients with history of neoplastic disease or those who develop cancer for the first time.
Few consensus guidelines and studies are available on the management of IBD patients with history of cancer. Most of the clinical data on the potentially detrimental effects of immunosuppressant therapy derives from observational studies of patients with rheumatologic diseases or solid organ transplants.
This chapter will offer (a) an understanding into the background cancer risk in IBD patients and (b) analysis and discussion of the risk of cancer related to IBD therapy and, finally, (c) suggest some clues for a multidisciplinary management.
KeywordsColorectal cancer Cancer risk Cancer recurrence Management
- Ali RAR, Dooley C, Comber H et al (2011) Clinical features, treatment, and survival of patients with colorectal cancer with or without inflammatory bowel disease. Clin Gastroenterol Hepatol 9:584-9.e1–584-9.e2Google Scholar
- Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR (2010) Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59:666–689CrossRefGoogle Scholar
- Collins PD, Mpofu C, Watson AJ, Rhodes JM (2006) Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2:CD000279Google Scholar
- Curtis RF, Freedman DM, Ron E, LAG R, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr (2006) New malignancies among cancer survivors: SEER Cancer registries, 1973–2000. National Cancer Institute, BethesdaGoogle Scholar
- Magro F, Gionchetti P, Eliakim R et al (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 11(6):649–670CrossRefGoogle Scholar